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(HCC) is its high vascularization, and as such, one of the most
appealing putative targets for anticancer therapies. HCC growth
largely depends on its ability to form new vessels (angiogenesis),
which guarantee supplying malignant cells with the oxygen and
nutrients needed for unrestricted proliferation [1]. The activation
of angiogenesis will ultimately lead to the invasion of tumor cells
into the new vessels and their metastatic spread. Several mole-
cules, mainly VEGF family members, produced by tumor cells
and cells within the microenvironment, orchestrate the recruit-
ment, activation, and organization of endothelial cells into a com-
plex architectural structure that constitutes the tumor vascular
system. This process requires several steps and molecular medi-
ators. However, even when the understanding of tumoral angio-
genesis has dramatically increased and numerous drugs are
currently available in the clinical setting [2], the mechanisms
involved in this process have not been completely understood.
In this issue of the Journal of Hepatology, Tsung-Chieh et al.
provide new evidence linking microRNA (miRNA) expression
and angiogenesis in HCC [3]. miRNAs, crucial regulators of gene
expression at the post-transcriptional level, have been shown to
participate in many biological events at both physiological and
pathological levels. They are involved in HCC pathogenesis, and
their expression proﬁles have been used to identify HCC subclass-
es [4]. A potential role of miRNA in angiogenesis has already been
suggested. A previous study showed that miR-107 inhibited HIF-
1b expression following hypoxia-induced activation of p53 [5]
and its overexpression in colon cancer cells inhibited angiogene-
sis and tumor growth in mice. Other examples are miR-15b and
miR-16, which have been shown to control the expression of
VEGF, a key pro-angiogenic factor particularly involved in tumor
angiogenesis [6]. In HCC, downregulation of miR-29b andJournal of Hepatology 20
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regulation of matrix metalloproteinase 2 (MMP2) and placenta-
growth factor (PGF), respectively [7,8].
The study by Tsung-Chieh et al. found a crosstalk between
miR-214 and the hepatoma-derived growth factor (HDGF), a pro-
moter of tumor angiogenesis. Also, ectopic expression of miR-214
suppressed tumor growth in a xenograft model of HCC as well as
microvascularity density in tumors and surrounding liver tissues
via HDGF secretion [3]. However, the role of miR-214 in tumori-
genesis is still controversial. Overexpression of miR-214 has been
reported in several tumors including lung and gastric cancers
while its downregulation has been shown in cervical cancer and
intrahepatic cholangiocarcinoma [9,10]. Inhibition of miR-214
resulted in enhanced proliferation, migration, and aggressiveness
in an experimental model of intrahepatic cholangiocarcinoma due
to upregulation of Twist, an important mediator of epithelial–
mesenchymal transition (EMT). These discrepancies may be par-
tially explained by the functional tissue-speciﬁcity of miR-214.
This context-dependency has been shown for other miRNAs such
as miR-29a that functions as a tumor suppressor in chronic lym-
phocytic leukemia and lung cancer and as an oncogene in breast
cancer [11].
The Food and Drug Administration (FDA) has approved differ-
ent anti-angiogenetic agents for the treatment of human malig-
nancies, including monoclonal antibodies (e.g. bevacizumab)
and tyrosine kinase inhibitors (e.g. sunitinib, sorafenib) [1]. In
HCC, sorafenib is the only systemic agent approved for patients
at advanced stages [12], and it has an anti-angiogenic activity
derived from its ability to block VEGFR2 and PDGFR2. Other
anti-angiogenics (e.g. linifanib, cediranib) are in clinical trials,
although their approval might be jeopardized by toxicity, a true
bottleneck for systemic drugs in patients with underlying liver
damage. For example, a phase III trial evaluating sunitinib, an
anti-angiogenic drug approved in renal cancer, was prematurely
stopped due to adverse effects and futility [13]. Also, a phase II
trial study with cediranib in advanced HCC patients was discon-
tinued because of the appearance of grade 3 toxicities in almost
all patients (93%) [14]. Unfortunately, a signiﬁcant number of
patients treated with anti-angiogenic therapies end up develop-
ing resistance, with molecular mechanisms not yet entirely12 vol. 57 j 490–491
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understood. Several hypotheses have been proposed, including
revascularization due to VEGF-independent mechanisms [15].
As the evidence supporting an active role of miRNAs in angi-
ogenesis is increasing, we need to speculate about how to trans-
late this knowledge into improvement in HCC management.
Targeting the miR-214/HDGF axis could provide additional anti-
angiogenic beneﬁts or show rescue potential in those patients
resistant to VEGF-based therapies. Notably, in the study by
Tsung-Chieh et al., the authors did not ﬁnd any correlation
between miRNA-214 and VEGF, suggesting that miR-214 could
regulate angiogenesis independently of VEGF. Strategies modu-
lating the expression of speciﬁc miRNAs have been developed
and are under investigation. Recent data from a phase II clinical
trial evaluating the safety and efﬁcacy of Miravirsen, the ﬁrst
miRNA-targeted drug entering clinical trials in patients with hep-
atitis C (HCV), showed targeted-speciﬁc inhibition of miR-122 (a
miRNA essential for HCV replication) and an acceptable tolerabil-
ity proﬁle [16]. However, there are no clinical trials currently
testing miRNA-based reagents in patients with HCC. At the pre-
clinical level, a previous study showed that restoring the expres-
sion of miR-26 using gene-therapy had dramatic effects in terms
of tumor growth inhibition in a mouse model of HCC, without
remarkable toxicity [17]. These ﬁndings certainly show that mod-
ulating miRNA expression could be a promising strategy, even
though further evidence is still needed.
The second aspect that will require further evaluation relates
to the lack of validated biomarkers for appropriate selection of
ideal candidates to receive anti-angiogenic therapies or to antic-
ipate resistance to VEGF-based inhibitors. In this context, the
use of miRNA as prognostic biomarkers is promising, as demon-
strated by the study from Ji et al., in which the expression of
miR-26 was an independent predictor of survival in HCC
resected patients, and identiﬁed those with a better response
to interferon therapy [18]. In conclusion, miRNAs have emerged
as a novel source of potential anti-angiogenic therapies in HCC.
Issues related to toxicity and off-target effects need to be con-
sidered, being still unclear whether they will end up having a
role in the management of this disease. Certainly, miRNA-based
anti-angiogenics could become an alternative to those patients
that progress after VEGF antagonism.Conﬂict of interest
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